| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13134* | 2021 |
| Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro SM Graham, HG Jørgensen, E Allan, C Pearson, MJ Alcorn, L Richmond, ... Blood, The Journal of the American Society of Hematology 99 (1), 319-325, 2002 | 1504 | 2002 |
| Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction M Copland, A Hamilton, LJ Elrick, JW Baird, EK Allan, N Jordanides, ... Blood 107 (11), 4532-4539, 2006 | 807 | 2006 |
| Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells C Bellodi, MR Lidonnici, A Hamilton, GV Helgason, AR Soliera, ... The Journal of clinical investigation 119 (5), 1109-1123, 2009 | 681 | 2009 |
| Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia T Holyoake, X Jiang, C Eaves, A Eaves Blood, The Journal of the American Society of Hematology 94 (6), 2056-2064, 1999 | 662 | 1999 |
| Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival A Hamilton, GV Helgason, M Schemionek, B Zhang, S Myssina, EK Allan, ... Blood, The Journal of the American Society of Hematology 119 (6), 1501-1510, 2012 | 487 | 2012 |
| Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells EM Kuntz, P Baquero, AM Michie, K Dunn, S Tardito, TL Holyoake, ... Nature medicine 23 (10), 1234-1240, 2017 | 457 | 2017 |
| Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib L Li, L Wang, L Li, Z Wang, Y Ho, T McDonald, TL Holyoake, WY Chen, ... Cancer cell 21 (2), 266-281, 2012 | 449 | 2012 |
| Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia B Zhang, YW Ho, Q Huang, T Maeda, A Lin, S Lee, A Hair, TL Holyoake, ... Cancer cell 21 (4), 577-592, 2012 | 403 | 2012 |
| Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells HG Jørgensen, EK Allan, NE Jordanides, JC Mountford, TL Holyoake Blood 109 (9), 4016-4019, 2007 | 393 | 2007 |
| Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia X Jiang, A Lopez, T Holyoake, A Eaves, C Eaves Proceedings of the National Academy of Sciences 96 (22), 12804-12809, 1999 | 314 | 1999 |
| Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling B Zhang, M Li, T McDonald, TL Holyoake, RT Moon, D Campana, L Shultz, ... Blood, The Journal of the American Society of Hematology 121 (10), 1824-1838, 2013 | 312 | 2013 |
| Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow TL Holyoake, FE Nicolini, CJ Eaves Experimental hematology 27 (9), 1418-1427, 1999 | 307 | 1999 |
| Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate B Zhang, AC Strauss, S Chu, M Li, Y Ho, KD Shiang, DS Snyder, ... Cancer cell 17 (5), 427-442, 2010 | 306 | 2010 |
| The chronic myeloid leukemia stem cell: stemming the tide of persistence TL Holyoake, D Vetrie Blood, The Journal of the American Society of Hematology 129 (12), 1595-1606, 2017 | 297 | 2017 |
| PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells P Neviani, JG Harb, JJ Oaks, R Santhanam, CJ Walker, JJ Ellis, ... The Journal of clinical investigation 123 (10), 4144-4157, 2013 | 259 | 2013 |
| Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry TH Brümmendorf, TL Holyoake, N Rufer, MJ Barnett, M Schulzer, ... Blood, The Journal of the American Society of Hematology 95 (6), 1883-1890, 2000 | 249 | 2000 |
| Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin–null mice H Glimm, W Eisterer, K Lee, J Cashman, TL Holyoake, F Nicolini, ... The Journal of clinical investigation 107 (2), 199-206, 2001 | 241 | 2001 |
| Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1 alpha in vivo DJ Dunlop, EG Wright, S Lorimore, GJ Graham, T Holyoake, DJ Kerr, ... | 240 | 1992 |
| Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells SA Abraham, LEM Hopcroft, E Carrick, ME Drotar, K Dunn, ... Nature 534 (7607), 341-346, 2016 | 237 | 2016 |
